Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience
This plain language summary describes a study in which researchers investigated a new tool called Raman spectroscopy in the detection and monitoring of blood cancer.
Read the full article here.
The original article on which this plain language summary is based is titled ‘Nanoparticle surface-enhanced Raman spectroscopy as a noninvasive, label-free tool to monitor hematological malignancy’ and was published in Nanomedicine. Read the original article here.
This plain language summary from Future Oncology describes long-term results from the RESONATE-2 study in which participants were treated with ibrutinib or with chlorambucil, and then followed for up to 8 years.
Read the full article here.
The original article on which this plain language summary is based is titled ‘Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia’ and was published in Blood Advances. Read the original article here.
This plain language summary describes a study that looked at the different tests used to detect a rare type of cancer called TRK (tropomyosin receptor kinase) fusion cancer in people taking part in three clinical trials testing the medication larotrectinib.
Read the full article here.
The original article on which this plain language summary is based is titled ‘Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib’ and was published in Cancer Genetics. Read the original article here.
This plain language summary published in Future Oncology describes results for the Black participants of the GRIFFIN clinical study, which looked at the treatment combination of daratumumab plus a standard therapy for multiple myeloma (called RVd therapy).
Read the full article here.
The original article on which this plain language summary is based is titled ‘Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN’ and was published in Blood Cancer Journal. Read the original article here.
The PROSPER study showed that patients treated with enzalutamide lived longer than patients treated with placebo. But do patients’ traits affect the how people respond to treatment? This plain language summary published in Future Oncology provides an overview of a study examining this question.
Read the full article here.
The original article on which this summary is based is called ‘Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region’ and was originally published in the journal European Journal of Cancer. The original article can be read here.